Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1960 1
1961 1
1964 1
1965 1
1966 1
1968 1
1969 1
1970 2
1972 2
1973 1
1975 1
1977 1
1978 1
1979 2
1980 3
1981 1
1982 2
1983 1
1984 2
1985 1
1986 1
1987 1
1989 1
1995 2
1996 2
1997 3
1998 1
1999 8
2000 7
2001 7
2002 14
2003 14
2004 18
2005 14
2006 11
2007 20
2008 10
2009 10
2010 21
2011 17
2012 16
2013 25
2014 15
2015 17
2016 17
2017 22
2018 26
2019 20
2020 23
2021 17
2022 16
2023 15
2024 8
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

381 results

Results by year

Filters applied: . Clear all
Page 1
Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis.
Al-Janabi A, Alabas OA, Yiu ZZN, Foulkes AC, Eyre S, Khan AR, Reynolds NJ, Smith CH, Griffiths CEM, Warren RB; BADBIR Study Group. Al-Janabi A, et al. JAMA Dermatol. 2024 Jan 1;160(1):71-79. doi: 10.1001/jamadermatol.2023.4846. JAMA Dermatol. 2024. PMID: 38055239 Free PMC article.
Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study.
Rodziewicz M, Dyball S, Lunt M, McDonald S, Sutton E, Parker B, Bruce IN; British Isles Lupus Assessment Group Biologics Register (BILAG-BR) consortium. Rodziewicz M, et al. Among authors: lunt m. Lancet Rheumatol. 2023 May;5(5):e284-e292. doi: 10.1016/S2665-9913(23)00091-7. Lancet Rheumatol. 2023. PMID: 38251591 Free article.
Reply.
Gwinnutt JM, Symmons DPM, Lunt M, Verstappen SMM. Gwinnutt JM, et al. Among authors: lunt m. Arthritis Rheumatol. 2017 Dec;69(12):2402-2403. doi: 10.1002/art.40311. Epub 2017 Nov 2. Arthritis Rheumatol. 2017. PMID: 28881421 No abstract available.
BayesGmed: An R-package for Bayesian causal mediation analysis.
Yimer BB, Lunt M, Beasley M, Macfarlane GJ, McBeth J. Yimer BB, et al. Among authors: lunt m. PLoS One. 2023 Jun 14;18(6):e0287037. doi: 10.1371/journal.pone.0287037. eCollection 2023. PLoS One. 2023. PMID: 37314996 Free PMC article. Clinical Trial.
Evaluation of serious infections, including Mycobacterium tuberculosis, during treatment with biologic disease-modifying anti-rheumatic drugs: does line of therapy matter?
Lauper K, Kearsley-Fleet L, Galloway JB, Watson KD; BSRBR-RA Contributors Group; Hyrich KL, Lunt M. Lauper K, et al. Among authors: lunt m. Rheumatology (Oxford). 2024 Jul 1;63(7):1957-1964. doi: 10.1093/rheumatology/kead515. Rheumatology (Oxford). 2024. PMID: 37758229 Free PMC article.
A prospective observational cohort study comparing the treatment effectiveness and safety of ciclosporin, dupilumab and methotrexate in adult and paediatric patients with atopic dermatitis: results from the UK-Irish A-STAR register.
Alexander H, Malek R, Prieto-Merino D, Gribaleva E, Baden M, Beattie P, Brown S, Burton T, Cameron S, Coker B, Cork MJ, Hearn R, Ingram JR, Irvine AD, Johnston GA, Lambert A, Lunt M, Man I, Newell L, Ogg G, Patel P, Wan M, Warren RB, Woolf R, Yiu ZZN, Reynolds N, Ardern-Jones MR, Flohr C. Alexander H, et al. Among authors: lunt m. Br J Dermatol. 2024 Nov 18;191(6):988-999. doi: 10.1093/bjd/ljae287. Br J Dermatol. 2024. PMID: 39044673 Free article.
381 results